PYXS vs. MGNX, RANI, ADCT, ACET, STTK, CVAC, CNTA, SPRY, TYRA, and ZNTL
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include MacroGenics (MGNX), Rani Therapeutics (RANI), ADC Therapeutics (ADCT), Adicet Bio (ACET), Shattuck Labs (STTK), CureVac (CVAC), Centessa Pharmaceuticals (CNTA), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry.
MacroGenics (NASDAQ:MGNX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
In the previous week, MacroGenics had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for MacroGenics and 5 mentions for Pyxis Oncology. MacroGenics' average media sentiment score of 1.00 beat Pyxis Oncology's score of 0.19 indicating that Pyxis Oncology is being referred to more favorably in the news media.
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by company insiders. Comparatively, 9.3% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MacroGenics has higher revenue and earnings than Pyxis Oncology. MacroGenics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
MacroGenics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
MacroGenics received 401 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 63.12% of users gave MacroGenics an outperform vote.
MacroGenics presently has a consensus price target of $12.00, indicating a potential upside of 193.40%. Pyxis Oncology has a consensus price target of $8.80, indicating a potential upside of 135.29%. Given Pyxis Oncology's higher probable upside, equities research analysts clearly believe MacroGenics is more favorable than Pyxis Oncology.
Pyxis Oncology has a net margin of 0.00% compared to Pyxis Oncology's net margin of -53.60%. MacroGenics' return on equity of -38.99% beat Pyxis Oncology's return on equity.
Summary
MacroGenics beats Pyxis Oncology on 9 of the 17 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
